# A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19.

> **NCT05246137** · PHASE3 · COMPLETED · sponsor: **Hipra Scientific, S.L.U** · enrollment: 2646 (actual)

## Conditions studied

- COVID-19
- SARS-CoV-2 Acute Respiratory Disease

## Interventions

- **BIOLOGICAL:** COVID-19 Vaccine 40 ug/dose

## Key facts

- **NCT ID:** NCT05246137
- **Lead sponsor:** Hipra Scientific, S.L.U
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-03
- **Primary completion:** 2022-03-03
- **Final completion:** 2023-03-03
- **Target enrollment:** 2646 (ACTUAL)
- **Last updated:** 2023-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05246137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05246137, "A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05246137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*